3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
To evaluate safety of reduction of dual antiplatelet therapy period to three months after
implantation of Ultimaster sirolimus-eluting stent (U-SES).
Additionally to investigate appropriateness of thienopyridine monotherapy with
discontinuation of aspirin.